Physician profile
Matthew Weinstein
NPI 1518240357
$5,629.98
in general payments reported to CMS, 2019-2025
24 companies · $788 in 2025
The $788 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $483 · 2020: $307 · 2021: $414 · 2022: $754 · 2023: $2,037 · 2024: $847 · 2025: $788.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,832 · Consulting Fee: $690 · Long Term Medical Supply Or Device Loan: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,831.72 |
| Consulting Fee | $690.00 |
| Long Term Medical Supply Or Device Loan | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,296.53 | 2019-2025 | Clareon, Centurion, Hydrus Microstent |
| Glaukos Corporation | $914.54 | 2022-2025 | Kxl System (Not Refurbished), Idosetr, Istent Infinite Trabecular Micro-Bypass System Model Is3 |
| Abbott Laboratories | $353.24 | 2022-2023 | Proclaim |
| Sight Sciences, INC. | $280.18 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $275.00 | 2019-2021 | |
| Ocular Therapeutix, INC. | $238.51 | 2024-2025 | Dextenza |
| Sun Pharmaceutical Industries INC. | $228.95 | 2019-2025 | Cequa |
| Horizon Therapeutics Plc | $215.96 | 2019-2022 | |
| Medtronic, INC. | $202.39 | 2022-2023 | Intellis Adaptivestim |
| Bausch & Lomb Americas INC. | $158.15 | 2025 | Vyzulta, Miebo |
| Abbvie INC. | $126.15 | 2024 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $57.61 | 2019 | |
| Dompe US, INC. | $37.58 | 2021-2024 | Oxervate |
| Allergan, INC. | $34.96 | 2020-2021 | |
| Oyster Point Pharma, INC. | $34.71 | 2024 | Ryzumvi, Tyrvaya |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $28.42 | 2024 | Tepezza |
| Mallinckrodt Enterprises LLC | $24.68 | 2019 | |
| Rxsight INC | $22.39 | 2023 | Rxsight Injector Handpiece, Rxsight Injector Cartridge, Rxsight Light Adjustable Lens (Rxlal) |
| Omeros Corporation | $18.44 | 2019 | |
| Abb Con-Cise Optical Group LLC | $17.82 | 2025 | Spectacle Lenses |
| Aerie Pharmaceuticals, INC. | $17.82 | 2019 | |
| Harrow Eye, LLC | $17.14 | 2024 | Iheezo |
| Novartis Pharmaceuticals Corporation | $16.62 | 2019 | |
| Eyevance Pharmaceuticals LLC | $12.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Weinstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.